Michael W. Jann

7.1k total citations
133 papers, 5.1k citations indexed

About

Michael W. Jann is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Michael W. Jann has authored 133 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Psychiatry and Mental health, 34 papers in Pediatrics, Perinatology and Child Health and 28 papers in Pharmacology. Recurrent topics in Michael W. Jann's work include Schizophrenia research and treatment (57 papers), Bipolar Disorder and Treatment (28 papers) and Pharmacological Effects and Toxicity Studies (23 papers). Michael W. Jann is often cited by papers focused on Schizophrenia research and treatment (57 papers), Bipolar Disorder and Treatment (28 papers) and Pharmacological Effects and Toxicity Studies (23 papers). Michael W. Jann collaborates with scholars based in United States, Taiwan and Canada. Michael W. Jann's co-authors include Stephen R. Saklad, Larry Ereshefsky, Y. W. Francis Lam, Wen‐Ho Chang, Kara Lee Shirley, Gary W. Small, W. Klugh Kennedy, Shih‐Ku Lin, Charlotte Davis and Scott Penzak and has published in prestigious journals such as American Journal of Psychiatry, PEDIATRICS and Biological Psychiatry.

In The Last Decade

Michael W. Jann

132 papers receiving 4.8k citations

Peers

Michael W. Jann

PMH

PHARM

PPCH

PHARM

C. Lindsay DeVane United States

Larry Ereshefsky United States

John S. Markowitz United States

Koichi Otani Japan

Paul J. Perry United States

Nicholas M. P. King United States

B. Müller‐Oerlinghausen Germany

Rik C. Schoemaker Netherlands

Pierre Baumann Switzerland

L. F. Gram Denmark

C. Lindsay DeVane United States

Michael W. Jann

1.8k ×0.9

PMH

1.3k ×1.1

PHARM

1.2k ×1.6

PPCH

1.2k ×1.6

PHARM

682 ×1.0

Citations per year, relative to Michael W. Jann Michael W. Jann (= 1×) peers C. Lindsay DeVane

Countries citing papers authored by Michael W. Jann

Since Specialization

Citations

This map shows the geographic impact of Michael W. Jann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Jann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Jann more than expected).

Fields of papers citing papers by Michael W. Jann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Jann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Jann. The network helps show where Michael W. Jann may publish in the future.

Co-authorship network of co-authors of Michael W. Jann

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Jann. A scholar is included among the top collaborators of Michael W. Jann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Jann. Michael W. Jann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jann, Michael W.. (2020). Do Asians Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Review. Indian Journal of Psychological Medicine. 42(1). 1–3. 6 indexed citations

Redfern, Jan S. & Michael W. Jann. (2019). The Evolving Role of Pharmacists in Transgender Health Care. Transgender Health. 4(1). 118–130. 28 indexed citations

Liu, Yijin, Michael W. Jann, Chad M. VanDenBerg, Chin B. Eap, & Shahab A. Shamsi. (2015). Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug–drug interaction. Journal of Chromatography A. 1420. 119–128. 28 indexed citations

Jann, Michael W., Kara Lee Shirley, & Gary W. Small. (2002). Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors. Clinical Pharmacokinetics. 41(10). 719–739. 280 indexed citations

Penzak, Scott, et al.. (2002). Influence of Ritonavir on Olanzapine Pharmacokinetics in Healthy Volunteers. Journal of Clinical Psychopharmacology. 22(4). 366–370. 42 indexed citations

VanDenBerg, Chad M., et al.. (2000). Disposition of olanzapine in Chinese schizophrenic patients. International Journal of Clinical Pharmacology and Therapeutics. 38(10). 482–485. 6 indexed citations

Chang, Wei‐Hau, et al.. (1999). In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology. 145(1). 91–98. 34 indexed citations

Jann, Michael W., et al.. (1998). Relative Bioavailability of Ondansetron 8‐mg Oral Tablets versus Two Extemporaneous 16‐mg Suppositories: Formulation and Gender Differences. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(2). 288–294. 28 indexed citations

Jann, Michael W.. (1998). Preclinical Pharmacology of Metrifonate. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(2P2). 55–67. 52 indexed citations

10.

ZumBrunnen, Troy L., et al.. (1998). Increased Lithium Serum and Red Blood Cell Concentrations During Ketorolac Coadministration. Journal of Clinical Psychopharmacology. 18(1). 33–37. 5 indexed citations

11.

Jann, Michael W., et al.. (1997). Venlafaxine and Nefazodone, Two Pharmacologically Distinct Antidepressants. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(3). 511–530. 17 indexed citations

12.

Lane, Hsien‐Yuan, et al.. (1997). Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Research. 69(2-3). 105–111. 24 indexed citations

13.

Jann, Michael W., et al.. (1996). Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 20(1). 73–86. 5 indexed citations

14.

Lane, Hsien‐Yuan, et al.. (1995). Haloperidol plasma concentrations in Taiwanese psychiatric patients.. PubMed. 94(11). 671–8. 12 indexed citations

15.

Milton, Grace V. & Michael W. Jann. (1995). Emergency Treatment of Psychotic Symptoms. Clinical Pharmacokinetics. 28(6). 494–504. 21 indexed citations

16.

Lin, Shih‐Ku, et al.. (1994). Disposition of Clozapine and Desmethylclozapine in Schizophrenic Patients. The Journal of Clinical Pharmacology. 34(4). 318–324. 25 indexed citations

17.

Pritchard, Walter S., Dennis W. Duke, Kerry L. Coburn, et al.. (1994). EEG-based, neural-net predictive classification of Alzheimer's disease versus control subjects is augmented by non-linear EEG measures. Electroencephalography and Clinical Neurophysiology. 91(2). 118–130. 140 indexed citations

18.

Jann, Michael W.. (1991). Clozapine. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 11(3). 179–195. 84 indexed citations

19.

Jann, Michael W., et al.. (1989). Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biological Psychiatry. 26(3). 239–249. 35 indexed citations

20.

Ereshefsky, Larry, Chester M. Davis, Charles A. Harrington, et al.. (1984). Haloperidol and Reduced Haloperidol Plasma Levels in Selected Schizophrenic Patients. Journal of Clinical Psychopharmacology. 4(3). 138???142–138???142. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact